Docetaxel injection, a subsidiary of Osaikang, passed the consistency evaluation of generic drugs

On May 12, Osaikang issued an announcement stating that its wholly-owned subsidiary has recently received the Docetaxel Injection "Drug Supplementary Application Approval Notice" approved and issued by the China Food and Drug Administration, and approved the drug to pass the generic drug with consistent quality and efficacy.

It is understood that docetaxel is a semi-synthetic taxane anti-tumor drug developed by the French company Sanofi.

Hexai injection was approved for marketing in Mexico and Europe in 1995, and was approved for marketing in the United States in May 1996; so far, it has been marketed in many countries around the world for breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer and Head and neck tumors and other indications have become one of the most commonly used or standard therapies for the treatment of these cancers.

Since anti-tumor effect, docetaxel uptake easier than taxol cells, inhibit microtubule depolymerization ability Taxus twice alcohol.
Docetaxel injection is one of the commonly used drugs for treating tumors, appeared in the "national basic health -care coverage, injury insurance and maternity insurance drug list.
" The specification of docetaxel injection developed by the subsidiary is 1ml:20mg, which has the advantages of no secondary dilution and convenient clinical use.
The PDB database shows that the sales of sample hospitals in 2020 will be 1.
112 billion yuan.
The market for docetaxel injection is mature and large.